Molecular Profile of FLT3-Mutated Relapsed/Refractory AML Patients in the Phase III ADMIRAL Study of Gilteritinib

Researchers provided insight into the relapsed or refractory (R/R) AML molecular profile and the impact of FLT3 inhibitors on mutational evolution associated with treatment resistance and benefit of gilteritinib across a wide spectrum of molecular and genetic subgroups in FLT3-mutated R/R AML.